Akademik Veri Yönetim Sistemi
9th Joint ECTRIMS-ACTRIMS Meeting, Milan, İtalya, 11 - 13 Ekim 2023, cilt.29, sa.3, ss.574-575
Introduction: Differential diagnosis of demyelinating diseases is
very crucial in order to optimize treatment, and diagnostic biomarkers
may be helpful for this purpose.
Objectives/Aims: In this study, we aimed to identify antibodybased
biomarkers that could help the differential diagnosis of
autoimmune demyelinating diseases.
Methods: We included 115 patients diagnosed with relapsingremitting
MS (RRMS, n=20) clinically isolated syndrome (CIS,
n=19), primary progressive MS (PPMS, n=15), benign MS
(n=19), opticospinal MS (OSMS, n=15), neuromyelitis optica
spectrum disease (NMOSD, n=9), recurrent optic neuritis (RON,
n=18) and 20 healthy controls. In order to investigate the presence
of auto-antibodies against neural membrane antigens that
may have diagnostic importance in these disease groups,immunostaining was performed in primary cortical neuron culture
with the sera of the cases and concurrently with astrocyte and
SH-SY5Y cell lines. Immunoprecipitation (IP) experiment was
performed on astrocyte and SH-SY5Y cell lines. Massspectrometry-
based proteomics screening was performed on IP
samples. The potential target antigens were selected by pathway
and gene ontology (GO) analyses. Home-made Enzyme-Linked
Immuno Sorbent Assay (ELISA) was performed to reveal the
presence of auto-antibodies against these target antigens in
patients' sera for validation
Results: As a result of proteomics analysis, only target antigens
detected in patient sera were evaluated among the membrane surface
proteins with a unique peptide value >3 and a false discovery
rate value <0.05. Analysis of IP samples obtained from SH-SY5Y
cell lines suggested the presence of anti-sorcin antibodies in
RRMS, but not in NMOSD and RON cases. ELISA experiments
which were held in different subtypes of MS and other demyelinating
diseases revealed higher titers of anti-sorcin antibodies
only in OSMS patients. Chloride intracellular channel protein
(CLIC1) antibody was detected in IP experiments with astrocyte
cells and was observed in OSMS and RON cases, but not in the
sera of NMOSD and RRMS patients.
Conclusion: The results obtained from proteomic studies suggest
that Sorcin and CLIC1 antibodies can be used as biomarkers in the
differential diagnosis of different demyelinating diseases. Further
studies with more patients are needed to show the serological status
of these antibodies in different demyelinating diseases.